Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 493-498

  Bodey, Bela ^a,e   Gröger, Angela M ^b   Bodey Jr , Bela ^a   Siegel, Stuart E ^c   Kaiser, Hans E ^b,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

A,B,C method of antigen detection; Antigen epitope retrieval; Apoptosis; Carcinogenesis; DNA repair; Genetic instability; Growth arrest and DNA damage inducible (GADD45) gene; Heat shock protein; Immunocytochemistry,; Malignant cell immunophenotype; Mouse anti human p53 monoclonal antibody; Mutant p53; Overexpression of p53; p21; Point mutation; Streptavidin biotin conjugation; Wild type p53

Indexed keywords

BIOTIN; FORMALDEHYDE; PARAFFIN; PEROXIDASE; PROTEIN P53; STREPTAVIDIN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; BREAST CARCINOMA; CELL DIFFERENTIATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYMUS; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA; DNA DAMAGE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; OSTEOSARCOMA; PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1842297584     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Marshall CJ: Tumor suppressor genes. Cell 64: 313-326, 1991.
2. Lane DP, Crawford LV: T-antigen is bound to host protein in SV40-transformed cells. Nature 278: 261-263, 1979.
3. Sarnow P, Ho YS, Williams J, Levine AJ: Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28: 387-394, 1982.
4. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
5. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
6. Kern S, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711, 1991.
7. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083-1091, 1991.
8. Marx J: New link found between p53 and DNA repair. Science 266: 1321-1322, 1994.
9. Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D: Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 87: 4766-4770, 1990.
10. Meek DW, Simon S, Kikkawa U, Eckhart W: The p53 tumor suppressor protein is phosphorylated ar serine 389 by casein kinase II. EMBO J 9: 3253-3260, 1990.
11. Sun Y, Nakamura K, Wendel E, Colburn NH: Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci USA 90: 2827-2831, 1993.
12. Eeles RA, Warren W, Knee G, Bartek J, Averill D, Stratton MR, Blake PR, Tait DM, Lane DP, Easton DF: Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 8: 1269-1276, 1993.
13. Goldblum JR, Bartos RE, Carr KA, Frank TS: Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am J Surg Pathol 17: 1244-1251,1993.
14. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN: Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 53: 2614-2617, 1993.
15. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990.
16. John J, Frech M, Wittinghofer A: Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation. J Biol Chem 263: 11792-11799, 1988.
17. Mazur M, Glickman BW: Sequence specificity of mutations induced by benzo[a]pyrene7,8-diol-9,10-epoxide at endogenous aprt gene in CHO cells. Somat Cell Mol Genet 14: 393-400, 1988.
18. Sturzbecher HW, Chumakov P, Welch WJ, Jenkins JR: Mutant p53 proteins bind hsp 72.73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1: 201-211, 1987.
19. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988.
20. Santoro A, Bonadonna G: Soft tissue and bone sarcomas. Cancer Chemother Biol Resp Modif 16: 617-624, 1996.
21. Dahlin DC, Coventry MB: Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg 49: 101-110, 1967.
22. Friedman MA, Carter SK: The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4: 482-510, 1972.
23. Rosen G: Neoadjuvant chemotherapy for osteogenic sarcoma: a model for the treatment of other highly malignant neoplasms. Recent Results Cancer Res 103: 148- 157, 1986.
24. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J: Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the multiinstitutional osteosarcoma study. Clin Orthop 270: 8-14, 1991.
25. Feugeas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon P, Babin S, Tnyss A, Hofman P, Terrier P, Kalifa C: Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14: 467-472, 1996.
26. Bruland OS: Cell surface markers on osteosarcoma cells. Possible targets for immunoscintigraphy and immunotherapy. Abstract. First internatl Meeting Interdisciplinary Res Osteosarcoma, Pittsburgh, Pennsylvania, p.75, October 16-18, 1991.
27. Ueda Y, Roessner A, Grundmann E: Pathological diagnosis of osteosarcoma: the validity of the subclassification and some new diagnostic approaches using immunohistochemistry. Cancer Treat Res 62: 109-124, 1993.
28. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP: Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169: 27-34, 1993.
29. Home GM, Anderson JJ, Tiniakos DG, Mclntosh GG, Thomas MD, Angus B, Henry JA, Lennard TW, Horne CH: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Brit J Cancer 73: 29-35, 1996.
30. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
31. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
32. Shi S-R, Cote C, Kalra KL, Taylor CR, Tandon AK: A technique for retrieving antigens in formal in-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40: 787-792, 1992.
33. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079- 1087, 1990.
34. Gohring UJ, Scharl A, Heckel C, Ahr A, Crombach G:p53 protein in 204 patients with primary breast carcinoma - immunohistochemical detection and clinical value as a prognostic factor. Arch Gynec Obst 256: 139-146, 1995.
35. Jaskiewicz K, Banach L, Izycka E: Hepatocellular carcinoma in young patients: histology, cellular differentiation, HBV infection and oncoprotein p53. Anticancer Res 75: 2723-2726, 1995.
36. Vojtesek B, Kovarik J, Nenutil R, Svitakova M, Zaloudik J, Dolezalova H, Rejthar A, Lauerova L: p53 protein expression associates with growth patterns rather than with metastasizing in operable breast cancer. Neoplasma 42: 331-336, 1995.
37. Bodey B, Kaiser HE, Goldfarb RH: Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Res 16: 517-531, 1996.
38. Fields S, Jung SK: Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049, 1990.
39. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
40. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ Jr: Interaction of p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266: 1376-1380, 1994.
41. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 353: 345-347, 1991.
42. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence J-J, May P, Oren M: p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 75: 1415-1423, 1993.
43. Kern SE, Pietenpol JA, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830, 1992.
44. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
45. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
46. Wang EH, Friedman PN, Prives C: The murine p53 protein blocks replication of SV40 in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57: 379-392, 1989.
47. Raycroft L, Wu H, Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249: 1049-1051, 1990.
48. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB: Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8: 2555-2559, 1993.
49. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703, 1991.
50. Carbon de Fromentel C, Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4: 1-15, 1992.
51. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor genes: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
52. Hollstein M, Sidransky D, Vogelstein R, Harris C: p53 mutations in human cancers. Science 253: 252-254, 1991.
53. Malkin D, Li FP, Strong LC, Fraumeni JF Jr. Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
54. Srivastava S, Zou ZO, Pirollo K Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-744, 1990.
55. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417, 1991.
56. Chen P, Iasarone A, Fick J, Edwards M, Prados M, Israel MA: Constitutional p53 mutations associated with brain tumors in young adults. Genet Cytogcnet 82: 106-115, 1995.
57. Kyritsis AP, Xu R, Bondy ML. Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Molec Carcinogen 15: 1-4, 1996.
58. Cho MY, Jung SH, Kim TS: p53 protein overexpression in astrocytic neoplasms. Yonsei Med J 36: 521-526, 1995.
59. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psych 59: 413-419, 1995.
60. Kordek R, Biemat W, Alwasiak J, Maculewicz R, Yanagihara R, Liberski PP: p53 protein and epidermal growth factor receptor expression in human astrocytomas. J Neuro-Oncol 26: 11-16, 1995.
61. Lee CS, Pirdas A, Lee MW: p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis. Australasian J Dermatol 36: 192-195, 1995.
62. Bergman R, Shemer A, Levy R, Friedman-Birnbaum R. Trau H, Lichtig C: Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions. Amer J Dermatopathol 77:547-550, 1995.
63. Sparrow LE, English DR, Heenan PJ, Dawkins HJ, Taran J: Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res 5: 387-392, 1995.
64. Weiss J, Heine M, Arden KC, Komer B, Pilch H, Herbst RA, Jung EG: Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res 139: 137-154, 1995.
65. Takahashi T, Nau MM, Chiba T, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
66. Miller CW, Simon K, Aslo A, Kok Y, Yokota J, Buys CHCM, Terada M, Koeffler HP: p53 mutations in human lung tumors. Cancer Res 52: 1695-1698, 1992.
67. Husgafvel-Pursiainen K, Ridanpaa M, Anttila S, Vainio H: p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occupat Environ Med 37: 68-76, 1995.
68. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 56: 72-76, 1996.
69. Boers JE, ten Velde GP, Thunnisscn FB: p53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Amer J Resp Crit Care Medicine 153: 411-416, 1996.
70. Kondo K, Tsuzuki H, Sasa M, Sumimoto M, Uyama T, Monden Y: The dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61: 20-26, 1996.
71. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP: Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56: 206-209, 1996.
72. Ozturk M: p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338: 1356-1359, 1991.
73. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 53: 4691-4694, 1993.
74. Tubor E: Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 42: 357-365, 1994.
75. Campbell IG, Eccles DM, Dunn B, Davis M, Leake V: p53 polymorphism in ovarian and breast cancer. Lancet 347: 393-394, 1996.
76. Callahan R: p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 84: 826-827, 1992.
77. Harris AL: p53 expression in human breast cancer. Adv Cancer Res 59: 69-88, 1992.
78. Eeles RA, Bartkova J, Lane DP, Bartek J: The role of TP53 in breast cancer development. Cancer Surv 18: 57-75, 1993.
79. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer, Breast Cancer Res Treat 32: 34-47, 1994.
80. Karameris AM, Worthy E, Gorgoulis VG, Quezado M, Anastassiades OT: p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. J Pathol 176: 361-372, 1995.
81. Ozbun MA, Butel JS: Turnor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66: 71-141, 1995.
82. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D. Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1946.
83. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Clealy K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weslon A, Modali R, Harris CC, Vogelstcin B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
84. Maltzman W, Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransforrned mouse cells. Mol Cell Biol 4: 1689-1694, 1984.
85. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
86. 1 phase arrest and p53 in human tumor cells. Cancer Res 55: 1842-1846, 1945.
87. Lee JM, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742-5746, 1993.
88. Lowe SW, Schmitt EM, Smith SW. Osbome BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
89. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaginc agents. Cancer Res 54: 5824-5830, 1994.
90. Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q. Kohn KW, Fornace AJ Jr, O'Connor PM: Disruption of p53 sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
91. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimuchi K: Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 53: 2884-2887, 1993.
92. Jetton TL, Liang Y, Pettepher CC, Zimmerman EC, Cox FG, Horvath K, Matschinsky FM, Magnuson MA: Analysis of upstream glucokinase promoter activity in transgenic mice and identification of giucokinase in rare neuroendocrine cells in the brain and gut. J Biol Chem 269: 3641-3654, 1994.
93. Schwartz MA, Denninghoff K: Alpha v integrins mediate the rise in intracellular calcium in endothelial cells on fibroneetin even though they play a minor role in adhesion. J Biol Chem 269: 11133-11137, 1994,
94. Taylor AH, Heavner G, Nedelman M, Sherris D, Brunt E, Knight D, Ghrayeh J: Lipopolysaccharide (LPS) neutralizing peptidcs reveal a lipid A binding site of LPS binding protein. J Biol Chem 270: 17934-17938, 1995.